These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 26481039)

  • 41. Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment.
    Cho SK; Kim D; Won S; Han M; Lee J; Jang EJ; Kim TH; Bae SC; Sung YK
    Semin Arthritis Rheum; 2017 Aug; 47(1):102-107. PubMed ID: 28216194
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F; Michaud K
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson KD; Lunt M; Mercer LK; Hyrich KL; Symmons DP; ;
    Arthritis Care Res (Hoboken); 2010 Jun; 62(6):755-63. PubMed ID: 20535785
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study.
    Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski M; Farley J
    J Rheumatol; 2014 Nov; 41(11):2129-36. PubMed ID: 25086079
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients.
    Thyagarajan V; Norman H; Alexander KA; Napalkov P; Enger C
    Semin Arthritis Rheum; 2012 Dec; 42(3):223-33. PubMed ID: 22748510
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study.
    Berghen N; Teuwen LA; Westhovens R; Verschueren P
    Clin Rheumatol; 2015 Oct; 34(10):1687-95. PubMed ID: 26219489
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study.
    Lee JL; Sinnathurai P; Buchbinder R; Hill C; Lassere M; March L
    Arthritis Res Ther; 2018 Aug; 20(1):171. PubMed ID: 30086795
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population.
    Mercer LK; Davies R; Galloway JB; Low A; Lunt M; Dixon WG; Watson KD; Symmons DP; Hyrich KL;
    Rheumatology (Oxford); 2013 Jan; 52(1):91-8. PubMed ID: 23238979
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors.
    Beukelman T; Xie F; Chen L; Horton DB; Lewis JD; Mamtani R; Mannion MM; Saag KG; Curtis JR
    Ann Rheum Dis; 2018 Jul; 77(7):1012-1016. PubMed ID: 29440001
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serious Infections in Rheumatoid Arthritis Offspring Exposed to Tumor Necrosis Factor Inhibitors: A Cohort Study.
    Vinet É; De Moura C; Pineau CA; Abrahamowicz M; Curtis JR; Bernatsky S
    Arthritis Rheumatol; 2018 Oct; 70(10):1565-1571. PubMed ID: 29771477
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong--the role of TNF blockers in an area of high tuberculosis burden.
    Tam LS; Leung CC; Ying SK; Lee GK; Yim CW; Leung YY; Kun EW; Wong KK; Li EK
    Clin Exp Rheumatol; 2010; 28(5):679-85. PubMed ID: 20822708
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapy with Biologic Agents After Diagnosis of Solid Malignancies: Results from the Corrona Registry.
    Pappas DA; Rebello S; Liu M; Schenfeld J; Li Y; Collier DH; Accortt NA
    J Rheumatol; 2019 Nov; 46(11):1438-1444. PubMed ID: 30936285
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis.
    Setoguchi S; Solomon DH; Weinblatt ME; Katz JN; Avorn J; Glynn RJ; Cook EF; Carney G; Schneeweiss S
    Arthritis Rheum; 2006 Sep; 54(9):2757-64. PubMed ID: 16947774
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: A meta-analysis of observational studies.
    Xie W; Yang X; Huang H; Gao D; Ji L; Zhang Z
    Semin Arthritis Rheum; 2020 Oct; 50(5):930-937. PubMed ID: 32906027
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
    Geborek P; Bladström A; Turesson C; Gulfe A; Petersson IF; Saxne T; Olsson H; Jacobsson LT
    Ann Rheum Dis; 2005 May; 64(5):699-703. PubMed ID: 15695534
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.
    Wolfe F; Michaud K
    Arthritis Rheum; 2007 May; 56(5):1433-9. PubMed ID: 17469100
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis.
    Lee WJ; Briars L; Lee TA; Calip GS; Suda KJ; Schumock GT
    Pharmacotherapy; 2016 Dec; 36(12):1201-1209. PubMed ID: 27779782
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype.
    Hellgren K; Di Giuseppe D; Smedby KE; Sundström C; Askling J; Baecklund E;
    Rheumatology (Oxford); 2021 Feb; 60(2):809-819. PubMed ID: 32810256
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.
    Chatzidionysiou K; Askling J; Eriksson J; Kristensen LE; van Vollenhoven R;
    Ann Rheum Dis; 2015 May; 74(5):890-6. PubMed ID: 24431398
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study.
    Barbulescu A; Delcoigne B; Askling J; Frisell T
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32669452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.